← All Os Therapies INC filings

Os Therapies INC 8-K filings

AMEX
OSTX
Os Therapies INC
8-K: OS Therapies Secures $6 Million in Private Placement to Advance Cancer Immunotherapy
OS Therapies has successfully priced a $6 million private placement to fund the clinical and regulatory milestones for its lead therapeutic candidate, OST-HER2.
AMEX
OSTX
Os Therapies INC
8-K: OS Therapies Announces Third Quarter 2024 Financial Results and Provides Business Update
OS Therapies reports its third quarter 2024 financial results, highlighting the completion of its Phase 2b clinical trial for OST-HER2 and anticipating topline data in December 2024.
AMEX
OSTX
Os Therapies INC
8-K: OS Therapies Secures $15 Million Equity Line with Square Gate Capital
OS Therapies has entered into an agreement with Square Gate Capital for a $15 million equity line, providing the company with flexible access to capital over the next 24 months.
AMEX
OSTX
Os Therapies INC
8-K: OS Therapies Bolsters Board with Biopharma Veterans Amidst Pivotal Trial Preparations
OS Therapies has appointed Avril McKean Dieser and Olivier R. Jarry to its Board of Directors, while accepting the resignations of Dr. Colin Goddard and Mr. Joacim Borg.
AMEX
OSTX
Os Therapies INC
8-K: OS Therapies Clarifies CUSIP for Common Stock Trading on NYSE American
OS Therapies has issued a clarification regarding the CUSIP identifier for its common stock, which is now trading under a new CUSIP on the NYSE American.
AMEX
OSTX
Os Therapies INC
8-K: OS Therapies Reports Second Quarter 2024 Financial Results and Successful IPO
OS Therapies announced its second quarter 2024 financial results, highlighted by a successful IPO that raised $6.4 million and the conversion of all preferred shares and debt into equity.